New hope for rare brain disease: Long-Term safety data collected
NCT ID NCT01887938
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study followed 24 people with metachromatic leukodystrophy (MLD), a rare and serious brain disease, who were already receiving an experimental drug called HGT-1110. The main goal was to check for side effects and immune reactions over a long period. Researchers wanted to see if the drug remained safe for continued use.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for METACHROMATIC LEUKODYSTROPHY (MLD) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
CHR Orleans - Hopital La Source
Orléans, 45067, France
-
CHU de Nantes
Nantes, 44093, France
-
Center for Pediatric Clinical Studies (CPCS)
Tübingen, Baden-Wurttemberg, 72076, Germany
-
Detska Interni Klinika, Lf Mu A Fn Brno
Brno, 61300, Czechia
-
Hopital Femme Mere Enfant
Bron, 69 677, France
-
Hopital Gui de Chauliac - CHRU de Montpellier
Montpellier, 34000, France
-
Hospital de Clinicas de Porto Alegre
Porto Alegre, 90035-003, Brazil
-
Hôpital de Bicêtre
Le Kremlin-Bicêtre, Île-de-France Region, 94275, France
-
Kitakyushu Municipal Yahata Hospital
Fukuoka, 805-8534, Japan
-
Klinikum Oldenburg
Oldenburg, 26133, Germany
-
Kurashiki Central Hospital
Okayama Prefecture, 710-8602, Japan
-
Marien-Hospital Wesel gGmbh
Wesel, 46483, Germany
-
Osaka University Hospital
Osaka, 565-0871, Japan
-
Rigshospitalet
Copenhagen, 2100, Denmark
-
The Children's Hospital at Westmead
Westmead, 2145, Australia
More trials for these conditions
Other studies related to the condition(s) this trial covers.